Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Fineline Cube Apr 9, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer

Fineline Cube Apr 9, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...

Company Drug

Yifan Pharma Secures NMPA Approval for Generic Sedapain

Fineline Cube Apr 9, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...

Company Drug

Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer

Fineline Cube Apr 9, 2025

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Company Deals

Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project

Fineline Cube Apr 9, 2025

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...

Company Deals

HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy

Fineline Cube Apr 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...

Policy / Regulatory

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes

Fineline Cube Apr 9, 2025

The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...

Company Drug

Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU

Fineline Cube Apr 9, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...

Company Deals

Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock

Fineline Cube Apr 9, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer

Fineline Cube Apr 9, 2025

Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...

Company Deals

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China

Fineline Cube Apr 9, 2025

Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...

Company

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales

Fineline Cube Apr 9, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...

Company Drug

Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia

Fineline Cube Apr 9, 2025

China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...

Company Medical Device

HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation

Fineline Cube Apr 9, 2025

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...

Company Drug

Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial

Fineline Cube Apr 9, 2025

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...

Posts pagination

1 … 122 123 124 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.